Quotient Limited (QTNT) Gross Profit Margin starting from the third quarter 2022 to third quarter 2021, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket
 


Quotient Limited  (NASDAQ: QTNT)


Quotient Limited's Gross Profit Margin by quarter

Trends, Rankings, Statistics



QTNT Gross Profit Margin (Dec 31 2022)
Q3
(Sep 30 2022)
Q2
(Jun 30 2022)
Q1
(Mar 31 2022)
Q4
(Dec 31 2021)
Q3
Y / Y Revenue Change -11.03 %
Seq. Revenue Change 3.56 %
Revenue In Millions $9.05
Gross Profit Margin 66.85 %
Gross Profit Margin Total Ranking # 2430
Gross Profit In Millions $6.05
Y / Y Gross Profit Change 169.61 %
Seq. Gross Profit Change -


Commenting Third Quarter 2022 Gross Profit Margin
Quotient Limited achieved Gross Profit of $6 millions compare to Gross Loss of $-12.26 millions recorded in the previous quarter. Revenue increased by 3.56 % Company accomplished above average Gross Profit Margin with 66.85 %.


Observing third quarter 2022 results within In Vitro & In Vivo Diagnostic Substances industry 12 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 2430, from total ranking in the previous quarter at 3324.
Learn about Gross Margin
QTNT's Gross Profit Margin third quarter 2022 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 13
Healthcare Sector # 433
Overall # 2388

Gross Profit Margin Statistics
High Average Low
72 % 47.25 % 22.06 %
(Sep 30 2020)   (Dec 31 2021)




Other Gross Profit Margin Profitability Ratios
QTNT's Cumulative Gross Profit Margin
In Vitro & In Vivo Diagnostic Substances Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
QTNT's Gross Profit Margin Profitability versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for QTNT's Competitors
Gross Profit Margin Profit Margin for Quotient Limited's Suppliers
Gross Profit Margin Profit Margin for QTNT's Customers

You may also want to know
QTNT's Annual Growth Rates QTNT's Profitability Ratios QTNT's Asset Turnover Ratio QTNT's Dividend Growth
QTNT's Roe QTNT's Valuation Ratios QTNT's Financial Strength Ratios QTNT's Gross Profit Growth
QTNT's Roa QTNT's Inventory Turnover Ratio QTNT's Growth Rates QTNT's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Dec 31 2022, within In Vitro & In Vivo Diagnostic Substances Industry Gross Profit MarginDec 31 2022 MRQ Gross ProfitDec 31 2022 MRQ Revenue
Myriad Genetics Inc   69.69 %$ 123.900  Millions$ 177.800  Millions
Quotient Limited  66.85 %$ 6.050  Millions$ 9.050  Millions
Lantheus Holdings Inc   63.52 %$ 167.171  Millions$ 263.166  Millions
Idexx Laboratories Inc  58.53 %$ 484.927  Millions$ 828.568  Millions
Aspira Women s Health inc   57.59 %$ 1.240  Millions$ 2.153  Millions
Meridian Bioscience Inc   55.37 %$ 31.505  Millions$ 56.902  Millions
Quidelortho Corp  52.05 %$ 451.042  Millions$ 866.541  Millions
Neogen Corporation  48.92 %$ 112.539  Millions$ 230.033  Millions
Heska Corporation  41.93 %$ 27.818  Millions$ 66.338  Millions
Trinity Biotech Plc  29.48 %$ 22.048  Millions$ 74.779  Millions
Alpha Teknova Inc   26.74 %$ 2.110  Millions$ 7.891  Millions
Immucell Corporation  25.37 %$ 0.992  Millions$ 3.911  Millions
Biomerica Inc   23.74 %$ 0.352  Millions$ 1.482  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.